亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

医学 危险系数 内科学 乳腺癌 肿瘤科 芳香化酶抑制剂 人口 中期分析 临床终点 癌症 安慰剂 转移性乳腺癌 妇科 三苯氧胺 帕博西利布 置信区间 随机对照试验 病理 替代医学 环境卫生
作者
Seock‐Ah Im,Yen‐Shen Lu,Aditya Bardia,Nadia Harbeck,Marco Angelo Colleoni,Fabio Andre Franke,Louis W.C. Chow,Joohyuk Sohn,Keun-Seok Lee,Saúl Campos-Gómez,Rafael Villanueva-Vázquez,Kyung-Hae Jung,Arunava Chakravartty,Gareth Hughes,Ioannis Gounaris,Karen Rodriguez-Lorenc,Tetiana Taran,Sara Alsterlind Hurvitz,Debu Tripathy
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:381 (4): 307-316 被引量:1001
标识
DOI:10.1056/nejmoa1903765
摘要

BACKGROUND: An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report the results of a protocol-specified interim analysis of the key secondary end point of overall survival. METHODS: We randomly assigned patients to receive either ribociclib or placebo in addition to endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen). Overall survival was evaluated with the use of a stratified log-rank test and summarized with the use of Kaplan-Meier methods. RESULTS: A total of 672 patients were included in the intention-to-treat population. There were 83 deaths among 335 patients (24.8%) in the ribociclib group and 109 deaths among 337 patients (32.3%) in the placebo group. The addition of ribociclib to endocrine therapy resulted in significantly longer overall survival than endocrine therapy alone. The estimated overall survival at 42 months was 70.2% (95% confidence interval [CI], 63.5 to 76.0) in the ribociclib group and 46.0% (95% CI, 32.0 to 58.9) in the placebo group (hazard ratio for death, 0.71; 95% CI, 0.54 to 0.95; P = 0.00973 by log-rank test). The survival benefit seen in the subgroup of 495 patients who received an aromatase inhibitor was consistent with that in the overall intention-to-treat population (hazard ratio for death, 0.70; 95% CI, 0.50 to 0.98). The percentage of patients who received subsequent antineoplastic therapy was balanced between the groups (68.9% in the ribociclib group and 73.2% in the placebo group). The time from randomization to disease progression during receipt of second-line therapy or to death was also longer in the ribociclib group than in the placebo group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.55 to 0.87). CONCLUSIONS: This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine therapy alone among patients with advanced hormone-receptor-positive, HER2-negative breast cancer. No new concerns regarding toxic effects emerged with longer follow-up. (Funded by Novartis; MONALEESA-7 ClinicalTrials.gov number, NCT02278120.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI65的应助被令狐大侠采纳,获得10
刚刚
Maestro_S的应助被令狐大侠采纳,获得10
刚刚
深情安青的应助被令狐大侠采纳,获得10
刚刚
alex的应助被令狐大侠采纳,获得10
1秒前
CodeCraft的应助被令狐大侠采纳,获得30
1秒前
Maestro_S的应助被令狐大侠采纳,获得30
1秒前
Maestro_S的应助被令狐大侠采纳,获得30
1秒前
DW的应助被令狐大侠采纳,获得10
1秒前
2秒前
2秒前
7秒前
美满惜雪发布了新的文献求助10
10秒前
拉长的映波完成签到,获得积分10
10秒前
huang完成签到 ,获得积分10
10秒前
臭臭完成签到,获得积分10
15秒前
香蕉觅云的应助被郭浩瑞采纳,获得10
21秒前
YIMISS完成签到,获得积分10
21秒前
Gloria完成签到 ,获得积分10
27秒前
慕青的应助被YIMISS采纳,获得10
30秒前
春日桑完成签到 ,获得积分10
31秒前
会撒娇的思萱完成签到,获得积分10
36秒前
37秒前
37秒前
siri发布了新的文献求助10
42秒前
mmyhn发布了新的文献求助10
43秒前
健康的怜菡完成签到,获得积分10
51秒前
臭臭发布了新的文献求助10
51秒前
u114768完成签到,获得积分10
58秒前
科研通AI6.3的应助被美满惜雪采纳,获得10
59秒前
siri完成签到,获得积分10
59秒前
痞老板死磕蟹黄堡完成签到 ,获得积分10
1分钟前
科研通AI6.3的应助被令狐大侠采纳,获得30
1分钟前
alex的应助被令狐大侠采纳,获得10
1分钟前
DW的应助被令狐大侠采纳,获得10
1分钟前
Hello的应助被令狐大侠采纳,获得10
1分钟前
Maestro_S的应助被令狐大侠采纳,获得30
1分钟前
机智的白卉的应助被令狐大侠采纳,获得10
1分钟前
科研通AI6.3的应助被令狐大侠采纳,获得10
1分钟前
科研通AI6.2的应助被令狐大侠采纳,获得10
1分钟前
在水一方的应助被令狐大侠采纳,获得30
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185000
求助须知:如何正确求助?哪些是违规求助? 9573966
关于积分的说明 21833855
捐赠科研通 7782482
什么是DOI,文献DOI怎么找? 3434468
关于科研通互助平台的介绍 2558673
邀请新用户注册赠送积分活动 2481178